Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Bayer Acquires Remaining 25% Stake in Bayer Zydus Pharma, Securing Full Ownership
With Bayer now assuming complete ownership of BZPPL, the company aims to further strengthen its presence and contribute to addressing healthcare needs in India.
- By PharmaNews Live Desk
- New Delhi
- May 03, 2024
Bayer Pharmaceuticals has finalized the acquisition of the remaining 25% stake in Bayer Zydus Pharma Private Limited, its joint venture with Zydus Lifesciences, for Rs. 282 crore. This move secures full ownership for Bayer in the joint venture, aligning with the agreed terms.
Established in 2011, the partnership aimed at bolstering pharmaceutical product sales and marketing in India.
With Bayer now assuming complete ownership of BZPPL, the company aims to further strengthen its presence and contribute to addressing healthcare needs in the country.
Leveraging Zydus Lifesciences' expertise and Bayer's global innovation capabilities, the joint venture has already made substantial progress in delivering innovative health solutions to Indian patients across various therapeutic areas.
Shweta Rai, Managing Director – India and Country Division Head – South Asia, Bayer’s Pharmaceuticals division, emphasized the success of the partnership, stating, "Zydus Lifesciences has been a formidable partner in our joint mission towards introducing best-in-class innovative health solutions and addressing the unmet healthcare needs of patients in India." Rai reaffirmed Bayer's commitment to maintaining a steadfast presence in India and continuing their mission of ‘Health for All, Hunger for None.’
Bayer, a global leader in the pharmaceutical industry, has a presence in over 100 countries. The company has developed innovative medicines across various therapeutic areas, including cardiovascular diseases, oncology, and women’s health.
Zydus Lifesciences, on the other hand, is a leading Indian pharmaceutical company with a focus on research and development. The company’s portfolio of products span from multiple therapeutic segments, including cardiovascular, gastrointestinal, to anti-infective medicines.
The acquisition of the remaining stake in Bayer Zydus Pharma represents a significant milestone for Bayer's strategic expansion in India.